-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Caris Life Sciences, Maintains $38 Price Target

Benzinga·11/05/2026 11:09:13
BTIG analyst Mark Massaro reiterates Caris Life Sciences (NASDAQ:CAI) with a Buy and maintains $38 price target.